Amgen licenses neurotrophic agents from Guilford:
This article was originally published in Clinica
Amgen has bought the worldwide rights to all human diagnostic and therapeutic applications of Guilford Pharmaceutical's FKBP-neuroimmunophilin ligands, a novel class of small molecule neurotrophic agents. Amgen will pay $35 million initially and $13.5 million over three years to support research at Guilford, plus milestone payments (of up to $392 million) and royalties. Amgen will develop, manufacture and market the products worldwide.
You may also be interested in...
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.